Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...
Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.
Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...
These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against ...
The hantavirus outbreak on the MV Hondius poses an ‘extremely low’ overall risk to the public, health officials said ...
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.
Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm.
March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing ...
After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results